Exelixis Inc
EXEL38.164USD
+0.734+1.96%
交易中 （美东）报价延迟15分钟
10.75B总市值
20.63市盈率 TTM
关于 Exelixis Inc 公司
Exelixis, Inc. 是一家肿瘤学公司。该公司已生产了四种上市药品，其中两种是其旗舰分子卡博替尼的配方。该公司还在推进和发展其产品线组合，包括其主要研究资产 zanzalintinib。卡博替尼是多种酪氨酸激酶的抑制剂，包括 MET、AXL、VEGF 受体和 RET，还被批准作为 CABOMETYX 片剂用于晚期肾细胞癌、先前治疗过的肝细胞癌和先前治疗过的放射性碘难治性分化性甲状腺癌，以及作为 COMETRIQ 胶囊用于进行性转移性髓样甲状腺癌。该公司的另外两种产品是 COTELLIC，一种 MEK 抑制剂，被批准作为多种联合方案的一部分用于治疗特定形式的晚期黑色素瘤，以及 MINNEBRO，一种口服、非甾体、选择性盐皮质激素受体阻滞剂，在日本被批准用于治疗高血压。
公司简介
公司代码EXEL
公司名称Exelixis Inc
上市日期Apr 11, 2000
成立日期1994
CEODr. Michael M. Morrissey, Ph.D.
员工数量1147
证券类型Ordinary Share
年结日Apr 11
公司地址1851 Harbor Bay Parkway
城市ALAMEDA
上市交易所NASDAQ Global Select Consolidated
国家United States of America
邮编94502
电话16508377000
网址https://www.exelixis.com/
公司代码EXEL
上市日期Apr 11, 2000
成立日期1994
公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Michael M. Morrissey, Ph.D.
Dr. Michael M. Morrissey, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
2.37M
+33.08%
Dr. Stelios B. Papadopoulos, Ph.D.
Dr. Stelios B. Papadopoulos, Ph.D.
Independent Chairman of the Board, Co-Founder
Independent Chairman of the Board, Co-Founder
1.26M
+0.15%
Mr. Jeffrey J. Hessekiel, J.D.
Mr. Jeffrey J. Hessekiel, J.D.
Executive Vice President, General Counsel
Executive Vice President, General Counsel
469.73K
+48.81%
Dr. Dana T. Aftab, Ph.D.
Dr. Dana T. Aftab, Ph.D.
Executive Vice President - Discovery and Translational Research, Chief Scientific Officer
Executive Vice President - Discovery and Translational Research, Chief Scientific Officer
391.52K
+51.34%
Mr. Patrick Joseph Haley
Mr. Patrick Joseph Haley
Executive Vice President - Commercial
Executive Vice President - Commercial
347.62K
+75.36%
Mr. Jack L. Wyszomierski
Mr. Jack L. Wyszomierski
Independent Director
Independent Director
337.77K
+2.73%
Dr. Amy C. Peterson, M.D.
Dr. Amy C. Peterson, M.D.
Executive Vice President, Product Development and Medical Affairs and Chief Medical Officer
Executive Vice President, Product Development and Medical Affairs and Chief Medical Officer
192.16K
+486.28%
Dr. George H. Poste, Ph.D.
Dr. George H. Poste, Ph.D.
Independent Director
Independent Director
150.18K
+1.27%
Dr. Maria C. Freire, Ph.D.
Dr. Maria C. Freire, Ph.D.
Independent Director
Independent Director
72.17K
+2.67%
Ms. Julie Anne Smith
Ms. Julie Anne Smith
Independent Director
Independent Director
763.00
-92.92%
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Michael M. Morrissey, Ph.D.
Dr. Michael M. Morrissey, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
2.37M
+33.08%
Dr. Stelios B. Papadopoulos, Ph.D.
Dr. Stelios B. Papadopoulos, Ph.D.
Independent Chairman of the Board, Co-Founder
Independent Chairman of the Board, Co-Founder
1.26M
+0.15%
Mr. Jeffrey J. Hessekiel, J.D.
Mr. Jeffrey J. Hessekiel, J.D.
Executive Vice President, General Counsel
Executive Vice President, General Counsel
469.73K
+48.81%
Dr. Dana T. Aftab, Ph.D.
Dr. Dana T. Aftab, Ph.D.
Executive Vice President - Discovery and Translational Research, Chief Scientific Officer
Executive Vice President - Discovery and Translational Research, Chief Scientific Officer
391.52K
+51.34%
Mr. Patrick Joseph Haley
Mr. Patrick Joseph Haley
Executive Vice President - Commercial
Executive Vice President - Commercial
347.62K
+75.36%
Mr. Jack L. Wyszomierski
Mr. Jack L. Wyszomierski
Independent Director
Independent Director
337.77K
+2.73%
收入明细
单位: USD更新时间: 4月6日 周日
单位: USD更新时间: 4月6日 周日
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
业务USD
名称
营收
占比
CABOMETYX
1.80B
82.92%
License revenues
349.24M
16.10%
COMETRIQ
11.16M
0.51%
Collaboration services revenues
10.06M
0.46%
地区USD
名称
营收
占比
U.S
1.82B
84.06%
Europe
318.63M
14.69%
Japan
27.08M
1.25%
业务
地区
业务USD
名称
营收
占比
CABOMETYX
1.80B
82.92%
License revenues
349.24M
16.10%
COMETRIQ
11.16M
0.51%
Collaboration services revenues
10.06M
0.46%
股东统计
更新时间: 2月21日 周五
更新时间: 2月21日 周五
持股股东
股东类型
持股股东
股东统计
占比
The Vanguard Group, Inc.
10.66%
BlackRock Institutional Trust Company, N.A.
9.69%
Farallon Capital Management, L.L.C.
8.51%
Renaissance Technologies LLC
5.55%
State Street Global Advisors (US)
4.14%
Other
61.45%
持股股东
股东统计
占比
The Vanguard Group, Inc.
10.66%
BlackRock Institutional Trust Company, N.A.
9.69%
Farallon Capital Management, L.L.C.
8.51%
Renaissance Technologies LLC
5.55%
State Street Global Advisors (US)
4.14%
Other
61.45%
股东类型
股东统计
占比
Investment Advisor/Hedge Fund
35.97%
Investment Advisor
33.06%
Hedge Fund
18.79%
Pension Fund
2.95%
Individual Investor
2.28%
Research Firm
1.77%
Sovereign Wealth Fund
1.22%
Bank and Trust
0.48%
Family Office
0.10%
Other
3.38%
机构持股
更新时间: 1月20日 周一
更新时间: 1月20日 周一
报告期
机构数
持股数
持股占比
持股变动
2025Q1
972
265.48M
94.85%
-6.82M
2024Q4
992
262.76M
93.66%
-11.36M
2024Q3
924
259.58M
90.96%
-10.18M
2024Q2
908
255.61M
87.75%
-22.29M
2024Q1
905
264.69M
87.26%
-20.82M
2023Q4
882
270.85M
87.07%
-16.64M
2023Q3
847
278.02M
87.32%
-18.15M
2023Q2
833
285.95M
87.85%
-21.34M
2023Q1
841
294.75M
90.97%
-14.08M
2022Q4
839
295.50M
91.62%
-5.46M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
The Vanguard Group, Inc.
29.37M
10.49%
+120.47K
+0.41%
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
26.71M
9.54%
-308.83K
-1.14%
Dec 31, 2024
Farallon Capital Management, L.L.C.
23.44M
8.37%
--
--
Mar 05, 2025
Renaissance Technologies LLC
15.30M
5.47%
-64.05K
-0.42%
Dec 31, 2024
State Street Global Advisors (US)
11.41M
4.08%
-31.73K
-0.28%
Dec 31, 2024
LSV Asset Management
8.17M
2.92%
+67.47K
+0.83%
Dec 31, 2024
Fuller & Thaler Asset Management Inc.
7.63M
2.73%
+708.31K
+10.23%
Dec 31, 2024
Geode Capital Management, L.L.C.
5.16M
1.84%
-5.12K
-0.10%
Dec 31, 2024
Dimensional Fund Advisors, L.P.
5.10M
1.82%
-153.57K
-2.92%
Dec 31, 2024
AQR Capital Management, LLC
3.97M
1.42%
+810.86K
+25.69%
Dec 31, 2024
查看更多
持股ETF
更新时间: 4月6日 周日
更新时间: 4月6日 周日
机构名称
占比
iShares Genomics Immunology and Healthcare ETF
4.81%
Tema Oncology ETF
4.2%
Alger Russell Innovation ETF
3.77%
First Trust NYSE Arca Biotechnology Index Fund
3.34%
Burney US Factor Rotation ETF
3.31%
Invesco Biotechnology & Genome ETF
2.89%
ERShares Entrepreneurs ETF
2.66%
First Trust Health Care Alphadex Fund
2.51%
Range Cancer Immunotherapy ETF
2.48%
Adaptiv Select ETF
2.04%
查看更多
iShares Genomics Immunology and Healthcare ETF
占比4.81%
Tema Oncology ETF
占比4.2%
Alger Russell Innovation ETF
占比3.77%
First Trust NYSE Arca Biotechnology Index Fund
占比3.34%
Burney US Factor Rotation ETF
占比3.31%
Invesco Biotechnology & Genome ETF
占比2.89%
ERShares Entrepreneurs ETF
占比2.66%
First Trust Health Care Alphadex Fund
占比2.51%
Range Cancer Immunotherapy ETF
占比2.48%
Adaptiv Select ETF
占比2.04%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据